Matinas BioPharma Holdings, Inc. Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

Stockholders??? Equity (Tables)

Stockholders’ Equity (Tables)

3 Months Ended

Mar. 31, 2021

Summary of Shareholders Equity Warrants Outstanding

	Shares
Outstanding at December 31, 2019		5,397
Issued		-
Exercised		(2,576	)
Tendered		-
Expired		(1,493	)
Outstanding at December 31, 2020		1,328	*
Issued		-
Exercised		(2	)**
Tendered		-
Expired		-
Outstanding at March 31, 2021		1,326	***

*	Weighted average exercise price for outstanding warrants is $0.55.
**	Converted into approximately 1 thousand shares of commons stock.
***	Weighted average exercise price for outstanding warrants is $0.54.

Basic and diluted net loss per common share

During the three months ended March 31, 2021 and 2020, diluted earnings per common share is the same as basic earnings per common share because, as the Company incurred a net loss during each period presented, the potentially dilutive securities from the assumed exercise of all outstanding stock options, warrants and conversion of preferred stock, would have an anti-dilutive effect. The following outstanding shares of potentially dilutive securities were excluded from the computation of diluted net loss per share attributable to common shareholders because including them would have been anti-dilutive as of March 31, 2021 and 2020:

	As of March 31,
	2021		2020
Stock options		22,890		20,562
Preferred Stock and accrued dividend upon conversion		10,123		9,104
Warrants		1,326		3,371
Total		34,339		33,037